Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Diclofenac sodium and orphenadrine citrate, the active ingredient in Neodolpasse, is a non‑steroidal anti‑inflammatory drug and muscle relaxant presented as a sterile injectable solution for intravenous use. It is used to manage moderate to severe pain, inflammatory conditions, and muscle spasm in adult patients.

GNH USA supplies Neodolpasse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neodolpasse combines an NSAID and a muscle relaxant to address pain‑related pathways and spastic muscle conditions.

- Moderate to severe pain: provides analgesia by reducing inflammation and relaxing skeletal muscle. - Inflammatory conditions: diminishes prostaglandin‑mediated swelling and discomfort. - Muscle spasm: alleviates involuntary muscle contractions through anticholinergic and NMDA‑receptor antagonism.

Adverse reactions may occur with any intravenous NSAID‑muscle‑relaxant combination.

Common Side Effects: - Injection site pain or erythema - Nausea or dyspepsia - Dizziness or headache - Mild transient hypotension - Elevated liver enzymes - Dry mouth or blurred vision

Serious or Rare Side Effects: - Severe gastrointestinal bleeding or ulceration - Anaphylactic or severe hypersensitivity reactions - Hepatotoxicity with marked transaminase rise - Renal impairment or acute kidney injury - Cardiac arrhythmias or myocardial infarction - Severe thrombocytopenia or coagulation disorders

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Assess renal and hepatic function: adjust use in impairment. - Review cardiovascular history: NSAIDs may increase thrombotic risk. - Evaluate for gastrointestinal ulcer disease: consider gastro‑protective measures. - Screen for asthma or allergic reactions to NSAIDs. - Monitor for signs of bleeding or hematologic abnormalities. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Neodolpasse may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: diclofenac may raise serum lithium levels. - Methotrexate: reduced clearance leading to toxicity. - ACE inhibitors or ARBs: heightened risk of renal impairment.

Moderate Interactions (Monitor Closely): - Diuretics: possible reduction in renal perfusion. - SSRIs or SNRIs: modest increase in bleeding tendency. - Corticosteroids: synergistic ulcerogenic effect. - Beta‑blockers: potential for additive hypotensive effect. - Anticholinergic drugs: may enhance dry‑mouth or blurred‑vision symptoms.